Section
Daily Life
7 pages in this section, most recently updated September 4, 2026. Each opens with a plain-English summary and cites its sources.
01 · Daily Life
FeaturedAlcohol on a GLP-1: what the labels say (almost nothing), what the trials found, and how to drink if you do
You'll get: The GLP-1 labels say nothing about alcohol. That is not the same as saying it is fine.
The GLP-1 labels carry no alcohol warning, but three other warnings intersect with drinking. What the labels say, what one trial found, and how to drink.
Updated September 4, 202602 · Daily Life
FeaturedSurgery, sedation and endoscopy on a GLP-1: the label aspiration warning and what the anaesthesia societies say to do
You'll get: Every GLP-1 label warns that food may stay in your stomach under anaesthesia or deep sedation, which risks inhaling it.
Every GLP-1 label warns about aspiration under general anaesthesia or deep sedation. The label text, the 2023 and 2024 society guidance, and what to do.
Updated September 4, 202603 · Daily Life
FeaturedNausea on a GLP-1: the label rates, when it peaks, and a management routine that clinicians actually recommend
You'll get: Nausea is the most common side effect on every GLP-1 label, reported by a quarter to nearly half of people in trials.
Nausea is the most common adverse reaction on every GLP-1 label. The trial rates, why escalation weeks are worst, what clinicians recommend, and red flags.
Updated September 4, 202604 · Daily Life
Hydration and constipation on a GLP-1: the kidney warning behind the water advice, and a constipation plan with sources
You'll get: Every GLP-1 label warns of kidney injury, mostly in people who got dried out from being sick. Water is the fix.
Every GLP-1 label warns of kidney injury from dehydration, and constipation affects up to a quarter of people on semaglutide. The labels, and a routine.
Updated September 4, 202605 · Daily Life
Hair shedding on a GLP-1: the label rates, why it is tied to weight loss, and what usually happens next
You'll get: Hair loss is on the Wegovy and Zepbound labels in about 3 to 6 percent of people, far more often in women.
Hair loss is on the Wegovy and Zepbound labels at 3 to 6 percent and tied to weight loss. What the labels report, what telogen effluvium is, what to ask.
Updated September 4, 202606 · Daily Life
FeaturedKeeping muscle on a GLP-1: what the body-composition substudies found and the protein and training evidence that answers them
You'll get: In the trial substudies, about a quarter to two fifths of the weight lost was lean mass. That is normal.
A quarter to two fifths of weight lost on semaglutide or tirzepatide in the trial substudies was lean mass. What that means, and what protects muscle.
Updated September 4, 202607 · Daily Life
FeaturedWhen a dose step is not going well: what the labels say about slowing down, staying put and stepping back
You'll get: The labels allow a prescriber to delay a dose increase, stay at a lower maintenance dose, or step back down.
The Wegovy and Zepbound labels set escalation schedules and the options when a step is not tolerated: delay, hold, or step down. What they permit.
Updated September 4, 2026